{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:25Z","timestamp":1783401325673,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Cape Town"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Juvenile dermatomyositis (JDM) is a rare pediatric autoimmune disease. A distinct clinical phenotype is associated with anti-melanoma differentiation-associated gene 5 (anti-MDA5) autoantibodies, which are linked to features such as arthritis, ulcerative skin lesions, and a heightened risk of interstitial lung disease (ILD), including its rapidly progressive form (RP-ILD). Despite increased recognition of this phenotype in East Asian, European, and North American populations, significant gaps remain in understanding its pathogenesis, and no consensus has been reached regarding optimal treatment strategies. Moreover, data on anti-MDA5-associated JDM in African populations are nonexistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the first three documented cases of anti-MDA5-positive JDM with ILD in African children. All patients exhibited characteristic extramuscular manifestations, and all had pulmonary involvement, which was rapidly progressive in two children, one of whom died. The clinical course, diagnostic findings, and treatment strategies are discussed in the context of existing literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of the literature was performed to evaluate the prevalence, clinical presentation, and treatment approaches for RP-ILD in anti-MDA5-associated JDM across different populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases highlight the wide heterogeneity of clinical phenotypes associated with anti-MDA5 autoantibodies in JDM. Given this variability, individualized monitoring and management strategies are essential to optimize outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08070-6","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:15:55Z","timestamp":1776838555000},"page":"4635-4646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MDA5-associated juvenile dermatomyositis and interstitial lung disease from rapidly progressive to silent: a report of three cases in South African children and a review of the literature"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3592-5347","authenticated-orcid":false,"given":"Maurane","family":"Lepage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehnaaz","family":"Akhalwaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zampoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nourse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashton","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Procter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanyisile","family":"Hlongwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanyia","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"8070_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/children11091046","volume":"11","author":"I Kobayashi","year":"2024","unstructured":"Kobayashi I (2024) Advances in juvenile dermatomyositis: pathophysiology, diagnosis, treatment and interstitial lung diseases-a narrative review. Children 11:1046. https:\/\/doi.org\/10.3390\/children11091046","journal-title":"Children"},{"key":"8070_CR2","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1093\/rheumatology\/keab108","volume":"60","author":"Y Yamasaki","year":"2021","unstructured":"Yamasaki Y, Kobayashi N, Akioka S, Yamazaki K, Takezaki S, Nakaseko H, Ohara A, Nishimura K, Nishida Y, Sato S, Kishi T, Hashimoto M, Mori M, Okazaki Y, Kuwana M, Ohta A (2021) Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology (Oxford) 60:4821\u20134831. https:\/\/doi.org\/10.1093\/rheumatology\/keab108","journal-title":"Rheumatology (Oxford)"},{"key":"8070_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/ar4600","volume":"16","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ, UK Juvenile Dermatomyositis Research Group (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16:R138. https:\/\/doi.org\/10.1186\/ar4600","journal-title":"Arthritis Res Ther"},{"key":"8070_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","volume":"60","author":"G Mamyrova","year":"2021","unstructured":"Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study Group (2021) Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford) 60:1839\u20131849. https:\/\/doi.org\/10.1093\/rheumatology\/keaa429","journal-title":"Rheumatology (Oxford)"},{"key":"8070_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0326-5","volume":"17","author":"G Giancane","year":"2019","unstructured":"Giancane G, Lavarello C, Pistorio A, Oliveira SK, Zulian F, Cuttica R, Fischbach M, Magnusson B, Pastore S, Marini R, Martino S, Pagnier A, Soler C, Sta\u0146\u0113vicha V, Ten Cate R, Uziel Y, Vojinovic J, Fueri E, Ravelli A, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2019) The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients. Pediatr Rheumatol Online J 17:24. https:\/\/doi.org\/10.1186\/s12969-019-0326-5","journal-title":"Pediatr Rheumatol Online J"},{"key":"8070_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00723-5","volume":"20","author":"K Nishi","year":"2022","unstructured":"Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G, Kamei K, Ito S (2022) Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol 20:60. https:\/\/doi.org\/10.1186\/s12969-022-00723-5","journal-title":"Pediatr Rheumatol"},{"key":"8070_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 54:784\u2013791. https:\/\/doi.org\/10.1093\/rheumatology\/keu385","journal-title":"Rheumatology (Oxford)"},{"key":"8070_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158:675\u2013677. https:\/\/doi.org\/10.1016\/j.jpeds.2010.11.033","journal-title":"J Pediatr"},{"key":"8070_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3899\/jrheum.101220","volume":"38","author":"N Sakurai","year":"2011","unstructured":"Sakurai N, Nagai K, Tsutsumi H, Ichimiya S (2011) Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. J Rheumatol 38:963\u2013964. https:\/\/doi.org\/10.3899\/jrheum.101220","journal-title":"J Rheumatol"},{"key":"8070_CR10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1310.2019.12.007","author":"J Hou","year":"2019","unstructured":"Hou J, Zhou ZX, Li JG, Xu YJ, Ding YC (2019) Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review. Zhonghua er ke za zhi = Chinese journal of pediatrics. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2019.12.007","journal-title":"Zhonghua er ke za zhi = Chinese journal of pediatrics"},{"key":"8070_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/24725625.2020.1832755","volume":"5","author":"C Quintana-Ortega","year":"2021","unstructured":"Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-Gonz\u00e1lez M, \u00c1lvarez-Rojas E, Udaondo C, Alcobendas R, Murias S (2021) Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Mod Rheumatol Case Rep 5:101\u2013107. https:\/\/doi.org\/10.1080\/24725625.2020.1832755","journal-title":"Mod Rheumatol Case Rep"},{"key":"8070_CR12","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1097\/RHU.0000000000001460","volume":"27","author":"M Shimizu","year":"2021","unstructured":"Shimizu M, Inoue N, Takeda Y, Kidouchi K, Fujita N, Fujiki T, Takasaki A, Adachi Y, Wada T (2021) Concurrent treatment with rituximab and plasma exchange for rapidly progressive interstitial lung disease complicating anti-MDA5 antibody-positive juvenile dermatomyositis. J Clin Rheumatol 27:S798\u2013S799. https:\/\/doi.org\/10.1097\/RHU.0000000000001460","journal-title":"J Clin Rheumatol"},{"key":"8070_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00595-1","volume":"19","author":"T-W Yeung","year":"2021","unstructured":"Yeung T-W, Cheong K-N, Lau Y-L, Tse K-CN (2021) Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J 19:103. https:\/\/doi.org\/10.1186\/s12969-021-00595-1","journal-title":"Pediatr Rheumatol Online J"},{"key":"8070_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063268","volume":"153","author":"K Ciaglia","year":"2024","unstructured":"Ciaglia K, Ghawji M, Caraballo M, Sloan E (2024) Successful treatment of rapidly progressive interstitial lung disease in juvenile dermatomyositis. Pediatrics 153:e2023063268. https:\/\/doi.org\/10.1542\/peds.2023-063268","journal-title":"Pediatrics"},{"key":"8070_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1497168","volume":"12","author":"L Qiu","year":"2024","unstructured":"Qiu L, Shao X, Ma L, Fan Z, Yu H (2024) Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review. Front Pediatr 12:1497168. https:\/\/doi.org\/10.3389\/fped.2024.1497168","journal-title":"Front Pediatr"},{"key":"8070_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/rheumato4010004","volume":"4","author":"S Bhandari","year":"2024","unstructured":"Bhandari S, Zickuhr L, Baral MR, Bhalla S, Jones H, Bucelli R, Sen D (2024) A review of MDA-5 dermatomyositis and associated interstitial lung disease. Rheumato 4:33\u201348. https:\/\/doi.org\/10.3390\/rheumato4010004","journal-title":"Rheumato"},{"key":"8070_CR17","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.autrev.2014.05.009","volume":"13","author":"D Poddighe","year":"2014","unstructured":"Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL (2014) A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. Autoimmun Rev 13:1142\u20131148. https:\/\/doi.org\/10.1016\/j.autrev.2014.05.009","journal-title":"Autoimmun Rev"},{"key":"8070_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00296-019-04442-1","volume":"40","author":"D Poddighe","year":"2020","unstructured":"Poddighe D, Dauyey K (2020) Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int 40:695\u2013702. https:\/\/doi.org\/10.1007\/s00296-019-04442-1","journal-title":"Rheumatol Int"},{"key":"8070_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00675-w","volume":"20","author":"JA Stewart","year":"2022","unstructured":"Stewart JA, Price T, Moser S, Mullikin D, Bryan A (2022) Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J 20:16. https:\/\/doi.org\/10.1186\/s12969-022-00675-w","journal-title":"Pediatr Rheumatol Online J"},{"key":"8070_CR20","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41390-024-03551-3","volume":"97","author":"P Vignesh","year":"2025","unstructured":"Vignesh P, Nadig PL, Basu S, Reddy S, Tyagi R, Dod A, Kumrah R, Garg R, Sharma S, Dhaliwal M, Pilania RK, Jindal A, Suri D, Rawat A, Singh S (2025) Profile of patients with juvenile dermatomyositis and anti-MDA5 autoantibodies. Pediatr Res 97:2020\u20132028. https:\/\/doi.org\/10.1038\/s41390-024-03551-3","journal-title":"Pediatr Res"},{"key":"8070_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565803","volume":"16","author":"S Lattarulo","year":"2025","unstructured":"Lattarulo S, Centrone F, Chironna M (2025) Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review. Front Immunol 16:1565803. https:\/\/doi.org\/10.3389\/fimmu.2025.1565803","journal-title":"Front Immunol"},{"key":"8070_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","volume":"40","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Wang L, Sun Y, Wang J, Lv C, You H, Xu L, Wang F, Zhang M, Tan W, Ke Y (2022) Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease. Clin Exp Rheumatol 40:292\u2013297. https:\/\/doi.org\/10.55563\/clinexprheumatol\/zmn18h","journal-title":"Clin Exp Rheumatol"},{"key":"8070_CR23","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study Group (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988\u2013995. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004","journal-title":"Ann Rheum Dis"},{"key":"8070_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, Taguchi Y, Katayama M, Tanizawa K, Handa T, Uozumi R, Akizuki S, Murakami K, Hashimoto M, Tanaka M, Ohmura K, Mimori T (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72:488\u2013498. https:\/\/doi.org\/10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"8070_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241294000","volume":"18","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zou R, Wei J, Tang C, Wang J, Lin M (2024) The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis. Ther Adv Respir Dis 18:17534666241294000. https:\/\/doi.org\/10.1177\/17534666241294000","journal-title":"Ther Adv Respir Dis"},{"key":"8070_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/bjd.17431","volume":"180","author":"N Okiyama","year":"2019","unstructured":"Okiyama N, Inoue S, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, Fujimoto M (2019) Antihelix\/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis. Br J Dermatol 180:1226\u20131227. https:\/\/doi.org\/10.1111\/bjd.17431","journal-title":"Br J Dermatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08070-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:12Z","timestamp":1783398432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8070"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08070-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents of all three patients for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}